Immune mechanisms of new therapeutic strategies in MS: teriflunomide.

Abstract

At present, a series of oral disease-modifying agents is being introduced for the treatment of multiple sclerosis. With the exception of laquinimod, the "new" oral compounds have already been approved for other indications such as organ transplantation (FTY720), psoriasis (dimethylfumarate), hairy cell leukemia (cladribine), and rheumatoid arthritis (leflunomide). Leflunomide is the prodrug of teriflunomide which is the latest compound that has successfully been tested in a large phase III clinical trial in relapsing MS. Due to its favorable safety profile and its efficacy in rheumatoid arthritis where the aberrant immune response is in various aspects similar to the autoimmune reaction in MS patients, teriflunomide is a promising treatment option for MS patients. Here, we review the most important cell biological and immunological modes of action of teriflunomide, report on the available data on its pharmacokinetics in humans, and summarize the recent clinical trials of teriflunomide in relapsing MS.

• Authors: Malte C Claussen, Thomas Korn
• Journal: Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 142 Issue 1 Pg. 49-56 (Jan 2012) ISSN: 1521-7035 [Electronic] United States
• PMID: 21367665 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2010 Elsevier Inc. All rights reserved.

Chemical References

• Anti-Inflammatory Agents
• Crotonates
• Hydroxybutyrates
• Nitriles
• Toluidines
• teriflunomide

Topics

• Animals
• Anti-Inflammatory Agents (pharmacokinetics, pharmacology)
• Clinical Trials as Topic
• Crotonates (pharmacokinetics, pharmacology)
• Humans
• Hydroxybutyrates
• Multiple Sclerosis (drug therapy)
• Nitriles
• Toluidines (pharmacokinetics, pharmacology)